Skip to content

Savara SVRA Tax Credit Income

Tax Credit Income at other companies

Heritage Financial logo
Heritage FinancialHFWA
$7.38M+22.9%
ADMA Biologics logo
ADMA BiologicsADMA
$470.75K
Nextpower Inc.
 logo
Nextpower Inc. NXT
$66.76M+190%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$13.37M-20.3%
TRV
Trevi Therapeutics, Inc.TRVI
$295.25K+5.8%
Proto Labs logo
Proto LabsPRLB
$136.75K

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept svra:TaxCreditIncome.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's tax credit income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's tax credit income?
Savara (SVRA) reported tax credit income of $853K in Q1 2026.
How has Savara's tax credit income changed year-over-year?
Savara's tax credit income increased by 8.8% year-over-year, from $784K to $853K.
What is the long-term trend for Savara's tax credit income?
Over 2 years (2021 to 2023), Savara's tax credit income has grown at a -4.5% compound annual growth rate (CAGR), from $873K to $797K.
What does tax credit income mean?
This metric represents the total value of tax credits recognized by the company during the reporting period, typically derived from research and development activities or government incentives. It reflects the company's ability to offset tax liabilities or receive direct financial benefits through specialized regulatory programs. For biopharmaceutical firms, this is a key indicator of the effective utilization of R&D tax incentives to manage cash burn.